# Eli Lilly and Company (LLY) — Q1-2026 Earnings Results

**Report date:** 2026-04-30 (before market open)  
**Sector:** Health Care / Pharmaceuticals  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/LLY/earnings/Q1-2026

## Analyst Estimates

- **Consensus EPS:** $6.84 (range $3.11–$7.77)
- **Consensus revenue:** $17840.00

## Post-Earnings Brief

### Headline

Eli Lilly Beats on EPS, Stock Up 9.8%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $8.55 | $6.84 | +21.07% |
| Revenue | N/A | $17.8B | N/A |

### Management Commentary

**Tone:** Unknown

No transcript is on record, and the analysis is based on numerical results only.

### Guidance Changes

No forward guidance data is available.

### What It Means

Eli Lilly's strong earnings per share of $8.55 significantly exceeded expectations, contributing to a 9.8% rise in stock price. The positive surprise in EPS indicates robust performance, although revenue figures were not disclosed. Investors may view this as a sign of the company's strong operational efficiency and potential growth.

## Pre-Earnings Brief

### Company Snapshot

Eli Lilly and Company (LLY) is a leading pharmaceutical company that develops and manufactures medications for various health conditions, including diabetes and cancer. With a market cap of $764 billion, it plays a significant role in the healthcare sector, focusing on innovative treatments that address unmet medical needs.

### Key Metrics to Watch

- **EPS** (consensus $6.84) — Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.
- **Revenue** (consensus $17.8B) — Total revenue reflects the company's sales performance and growth potential, which is crucial for understanding market demand for its products.

### Last Quarter Recap

In the last quarter, Eli Lilly reported an EPS of $7.54, exceeding estimates by 7.88%, which positively impacted the stock price. However, revenue figures were not disclosed, leaving some uncertainty about overall sales performance.

**Management promises last quarter:**

- Focus on expanding its diabetes and cancer treatment portfolios.
- Commitment to maintaining strong research and development efforts.
- Plans to enhance global market access for its key products.

### Wall Street Expectations

Analysts expect Eli Lilly to report strong earnings driven by its innovative drug portfolio, with a consensus EPS of $6.84. However, there are concerns about potential pricing pressures and competition in the pharmaceutical market.

**Bull case:** If Eli Lilly beats EPS expectations and shows robust revenue growth, it could signal strong demand for its products, leading to a positive stock reaction.

**Bear case:** If the company misses EPS estimates or provides weak guidance, it could raise concerns about its growth trajectory and lead to a negative market response.

### Options Signal

Implied move: **6.42%**

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

### Earnings Track Record

| Quarter | EPS Surprise | 1-Day Reaction |
|---|---|---|
| Q4-2025 | +7.88% | +10.33% |
| Q3-2025 | +16.59% | +3.81% |
| Q2-2025 | +14.08% | -14.14% |
| Q1-2025 | -5.01% | -11.66% |

### Pivotal Questions

1. **Will Eli Lilly's EPS exceed the consensus estimate of $6.84?**
   - Why it matters: A beat on EPS could indicate strong operational performance and boost investor confidence.
2. **What guidance will management provide for future revenue growth?**
   - Why it matters: Management's outlook on revenue growth will be critical for assessing the company's ability to sustain its momentum.

### Thesis Break Levels

- **Bull trigger:** Eli Lilly must report an EPS above $7.00 and provide strong revenue guidance to confirm the bull case.
- **Bear trigger:** An EPS below $6.50 or weak revenue guidance would support the bear case.

Investors are closely watching how the company balances growth with potential pricing pressures in the pharmaceutical market.

### Scenario Playbook

- **Beat & raise:** If Eli Lilly beats expectations, history suggests a potential stock increase of around +3.13%, confirming strong demand for its products.
- **In-line / cautious:** If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.
- **Miss:** Should the company miss earnings expectations, history suggests a potential decline of around -8.97%, raising concerns about future growth.

### What the Street is Missing

The Street may be underestimating the impact of Eli Lilly's recent product launches, which could drive higher-than-expected sales.

**Supporting points:**

- The company has consistently beaten EPS estimates in recent quarters, indicating strong operational performance.
- Options are pricing a 6.42% move, but the stock has historically moved more than that, suggesting potential for a larger reaction.

**Risk to consensus:** If the company reports strong sales growth in its key therapeutic areas, it could challenge the current consensus.

### What to Listen For

- Updates on the performance of diabetes and cancer drugs.
- Any commentary on pricing strategies and market competition.
- Insights into research and development progress for new treatments.
- Management's outlook on global market expansion efforts.
- Details on cost management and operational efficiencies.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/LLY/earnings/Q1-2026_